Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of A 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700) in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months

NCT07333352 is registered in ClinicalTrials.gov with Reinovax Biologics Co., LTD as lead sponsor.

NCT NCT07333352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07333352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of A 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700) in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
Lead sponsor
Reinovax Biologics Co., LTD
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2025
Completion date
April 14, 2026
Enrollment
480 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infectious disease